Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma
April 09, 2024 02:00 ET
|
Essential Pharma
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma First development-stage asset to be added to the Essential Pharma...
Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma
August 01, 2023 07:00 ET
|
Renaissance Pharma
Press Release Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma ...
Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma
August 01, 2023 03:00 ET
|
Renaissance Pharma
Press Release Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma ...
Neuroblastoma Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Y-mabs therapeutics, Clarity Pharmaceuticals, K C Pharmaceuticals, Exelixis, Eli Lilly and Company, Innervate Radiopharmaceuticals, and Others Expected to Pr
April 20, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 20, 2023 (GLOBE NEWSWIRE) -- Neuroblastoma Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Y-mabs therapeutics, Clarity Pharmaceuticals, K C...
Neuroblastoma Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 25+ Companies Working in the Domain
November 16, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Neuroblastoma Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 25+ Companies Working in the Domain DelveInsight’s...
Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine
November 30, 2020 07:00 ET
|
Autolus Therapeutics plc
- Findings from the Phase 1 study provide evidence that AUTO6 induces clinical activity in this solid tumor setting without inducing on-target off-tumor toxicity - AUTO6NG builds on this approach...
Autolus Therapeutics and Noile-Immune Announce Licensing Agreement
November 13, 2019 06:30 ET
|
Autolus Therapeutics plc
LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Noile-Immune...
Autolus Therapeutics Presents Preclinical Data on AUT06NG at the SITC Annual Meeting
November 09, 2019 07:00 ET
|
Autolus Therapeutics plc
LONDON, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment...
Autolus Announces Data Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 03, 2019 09:08 ET
|
Autolus Therapeutics plc
LONDON, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Article on anti-tumor activity of PV-10 against relapsed and refractory neuroblastoma published in OncoTargets and Therapy
February 19, 2019 07:30 ET
|
Provectus Biopharmaceuticals Inc.
Provides preclinical proof-of-concept data on efficacy of single-agent PV-10 for treatment of neuroblastomaSupports use of checkpoint inhibitors with PV-10 treatment backbone to further enhance...